Technology for Tumor Boards & Trial Recruitment
We have developed the first ever, open source, cloud-based, asynchronous tumor board technology to enhance the utility of patient molecular profiling data from CLIA-certified/CAP-accredited molecular diagnostic (MolDx) tests for individualized cancer treatment planning. This data will be combined with patient records and a global knowledgebase that links variants to drug sensitivity based on the work done with the Pancreatic Cancer Action Network and Perthera Inc. to orchestrate a precision medicine operation called “Know Your Tumor” (KYT).
Collaborators: Perthera Inc.
Sponsor: Pancreatic Cancer Advocacy Network
Information on patients that completed the KYT program:
Total # of patients that completed the KYT program: 640
# of patients that utilized a report-listed therapy: 126
Subset of patients with highly actionable biomarkers: 35
#of patients who utilized molecularly targeted therapies, either off label or in clinical trials: 17